As you might know, Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) just kicked off its latest quarterly results with some very strong numbers. The company beat expectations with revenues of ر.س3.0b arriving 9.6% ahead of forecasts. Statutory earnings per share (EPS) were ر.س1.70, 3.0% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Taking into account the latest results, the most recent consensus for Dr. Sulaiman Al Habib Medical Services Group from ten analysts is for revenues of ر.س13.5b in 2025. If met, it would imply a major 28% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to step up 17% to ر.س7.46. Before this earnings report, the analysts had been forecasting revenues of ر.س13.6b and earnings per share (EPS) of ر.س7.58 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

There were no changes to revenue or earnings estimates or the price target of ر.س300, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Dr. Sulaiman Al Habib Medical Services Group, with the most bullish analyst valuing it at ر.س347 and the most bearish at ر.س245 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Dr. Sulaiman Al Habib Medical Services Group's rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 13% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Dr. Sulaiman Al Habib Medical Services Group to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Dr. Sulaiman Al Habib Medical Services Group analysts - going out to 2026, and you can see them free on our platform here.

Sulaiman Al Habib Medical Services Group (1 is potentially serious!) that you need to take into consideration.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.